BusinessActinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 6, 2016, 2:00 AM UTC
BusinessImmune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex Delivering Multiple Tumor Antigens (Conserved and Neo-Antigens) and G100 For Intratumoral ImmunotherapyBy Nasdaq OMXDec 5, 2016, 1:01 PM UTC
BusinessImmune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex Delivering Multiple Tumor Antigens (Conserved and Neo-Antigens) and G100 For Intratumoral ImmunotherapyBy Nasdaq OMXDec 5, 2016, 1:01 PM UTC
BusinessKura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsBy Nasdaq OMXDec 1, 2016, 12:30 PM UTC
BusinessMats Wahlström Joins Surefire Medical Board of DirectorsBy Nasdaq OMXNov 30, 2016, 11:00 AM UTC
BusinessActinium Further Strengthens Clinical Development Team with Senior Hire to Support Later-Stage Clinical TrialsBy Nasdaq OMXNov 29, 2016, 12:00 PM UTC
BusinessActinium Issues Letter to Shareholders Highlighting 2016 Accomplishments and Anticipated Milestones for 2017By Nasdaq OMXNov 22, 2016, 12:00 PM UTC
BusinessActinium Pharmaceuticals to Present at LD Micro Main Event Investor ConferenceBy Nasdaq OMXNov 21, 2016, 12:00 PM UTC
